Cancer and Immune Response: Old and New Evidence for Future Challenges.
dc.contributor.author | De la Cruz-Merino, Luis | |
dc.contributor.author | Grande-Pulido, E. | |
dc.contributor.author | Albero-Tamarit, Ana | |
dc.contributor.author | Codes-Manuel de Villena, Manuel Eduardo | |
dc.date.accessioned | 2024-01-23T12:03:24Z | |
dc.date.available | 2024-01-23T12:03:24Z | |
dc.date.issued | 2008 | |
dc.description.abstract | Cancer may occur as a result of abnormal host immune system tolerance. Recent studies have confirmed the occurrence of spontaneous and induced antitumor immune responses expressed as the presence of tumor-infiltrating T cells in the tumor microenvironment in some cancer models. This finding has been recognized as a good prognostic factor in several types of tumors. Some chemotherapy agents, such as anthracyclines and gemcitabine, are effective boosters of the immune response through tumor-specific antigen overexpression after apoptotic tumor cell destruction. Other strategies, such as GM-CSF or interleukin-2, are pursued to increase immune cell availability in the tumor vicinity, and thus improve both antigen presentation and T-cell activation and proliferation. In addition, cytotoxic T lymphocyte antigen 4 – blocking monoclonal antibodies enhance immune activity by prolonging T-cell activation. Strategies to stimulate the dormant immune system against tumors are varied and warrant further investigation of their applications to cancer therapy in the future. | spa |
dc.description.extent | 751 KB | spa |
dc.identifier.doi | 10.1634/theoncologist.2008-0166 | spa |
dc.identifier.issn | 1549-490X | spa |
dc.identifier.uri | https://hdl.handle.net/10641/3802 | |
dc.language.iso | eng | spa |
dc.publisher | The Oncologist | spa |
dc.relation.publisherversion | https://academic.oup.com/oncolo/article/13/12/1246/6397403?login=false | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.accessRights | metadata only access | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | Cancer | spa |
dc.subject | Tumor-infiltrating lymphocytes | spa |
dc.subject | Immune tolerance | spa |
dc.subject | Cancer vaccines | spa |
dc.subject | CTLA-4 | spa |
dc.subject | GM-CSF | spa |
dc.subject | IL-2 | spa |
dc.title | Cancer and Immune Response: Old and New Evidence for Future Challenges. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | SMUR | spa |
dspace.entity.type | Publication |